These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 27987249)

  • 1. Achondroplasia: Development, pathogenesis, and therapy.
    Ornitz DM; Legeai-Mallet L
    Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
    Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
    Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
    Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
    Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
    Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
    Tanaka H
    Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
    Foldynova-Trantirkova S; Wilcox WR; Krejci P
    Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
    Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia.
    Martínez-Frías ML; de Frutos CA; Bermejo E; Nieto MA;
    Am J Med Genet A; 2010 Jan; 152A(1):245-55. PubMed ID: 20034074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
    Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR3-related condition: a skeletal dysplasia with similarities to thanatophoric dysplasia and SADDAN due to Lys650Met.
    Farmakis SG; Shinawi M; Miller-Thomas M; Radmanesh A; Herman TE
    Skeletal Radiol; 2015 Mar; 44(3):441-5. PubMed ID: 25119967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3.
    Naski MC; Colvin JS; Coffin JD; Ornitz DM
    Development; 1998 Dec; 125(24):4977-88. PubMed ID: 9811582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
    Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
    PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.
    Mugniery E; Dacquin R; Marty C; Benoist-Lasselin C; de Vernejoul MC; Jurdic P; Munnich A; Geoffroy V; Legeai-Mallet L
    Hum Mol Genet; 2012 Jun; 21(11):2503-13. PubMed ID: 22367969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies.
    Kunova Bosakova M; Varecha M; Hampl M; Duran I; Nita A; Buchtova M; Dosedelova H; Machat R; Xie Y; Ni Z; Martin JH; Chen L; Jansen G; Krakow D; Krejci P
    Hum Mol Genet; 2018 Mar; 27(6):1093-1105. PubMed ID: 29360984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.
    Chen L; Li C; Qiao W; Xu X; Deng C
    Hum Mol Genet; 2001 Mar; 10(5):457-65. PubMed ID: 11181569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
    Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
    Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
    Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
    Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.